Stock Analiz

Immunovant, Inc. IMVT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$34.18Market cap $7.1B
Open the interactive analysis →

Immunovant, Inc. (IMVT) is a healthcare company listed in the US with a market value of about $7.1B.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B10.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal year20262025202420232022202120202019
Revenue————————
Net income-$506M-$414M-$259M-$211M-$157M-$107M-$66M-$29M
Free cash flow-$407M-$377M-$215M-$188M-$106M-$84M-$53M-$29M
EPS (diluted)$-2.77$-2.73$-1.88$-1.71$-1.43$-1.22$-1.54$-1.29
Net margin————————
ROIC————————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 16 analysts is $48.50, 42% above the current price; targets range from $33.00 to $62.00; the consensus rating is “Buy”; expected EPS is $-2.44 for the fiscal year ending March 31, 2027.

Frequently asked questions

Does Immunovant pay a dividend?

Not currently.

Is Immunovant a good stock to buy?

We do not give buy or sell advice. Immunovant scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

AMGNAmgen2.4GILDGilead Sciences2.8MRNAModerna1.0ARGXArgenx2.4BIIBBiogen1.8RVMDRevolution Medicines0.6

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.